• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    o/w emulsions comprising semifluorinated alkanes. the invention provides liquid compositions in the form of physically stable emulsions comprising a semifluorinated alkane. the semifluorinated alkane is comprised in the step which may also include an active pharmaceutical ingredient. one of the preferred active ingredients is propofol. the compositions are optionally heat sterilizable and can be used for cosmetic or pharmaceutical product applications, and administered topically, intravenously or via other routes.
    公开号:BR112013016661B1
    申请号:R112013016661-4
    申请日:2012-01-03
    公开日:2021-08-03
    发明作者:Bastian Theisinger；Sonja Theisinger；Bernhard Gunther
    申请人:Novaliq Gmbh；
    IPC主号:
    专利说明:

    BACKGROUND DESCRIPTION
    Pharmaceutical emulsions play a key role in the field of dermatology, where they provide skin-friendly vehicles for many topical drugs. Occasionally, emulsions are also used for oral and parenteral medications, in particular for the intravenous administration of very poorly water-soluble active ingredients such as propofol (marketed, for example, as Disoprivan® or Diprivan® and etomidate (marketed as Etomidat® Lipuro).
    Propofol (2,6-diisopropyl phenol, PM 178.27) is a potent intravenous anesthetic. It is routinely used for both induction and maintenance of anesthesia. In addition, it can be used for sedation of patients in intensive care or in the preparation of local or regional anesthesia for surgical and diagnostic procedures. It is characterized by its rapid onset of action and its relatively mild side effects.
    Physically, propofol is a highly lipophilic compound that melts at approximately 19°C. At room temperature it has the appearance of an oil. Its solubility in water or aqueous buffers is negligible, which makes propofol a highly challenging compound to formulate, particularly for intravenous administration, but also for other routes. The only ionizable group of the molecule is its hydroxyl group, which is, however, unsuitable for forming a water-soluble salt due to its pKa of 11. The octanol/water partition coefficient for propofol is 6761:1 at a pH of 6-8.5.
    Propofol was first developed by the British pharmaceutical company ICI (now AstraZeneca) as a solubilized intravenous formulation that contained substantial amounts of the solubilizer Cremophor® EL, an excipient that is not very well tolerated. Shortly after market introduction, several reports of anaphylactic reactions led to the formulation being withdrawn. Several years later, AstraZeneca launched a new formulation of propofol marketed as Diprivan® that is still used today. This product is an o/w emulsion comprising 1% propofol and 10% soybean oil as the dispersed phase and 1.2% purified egg lecithin as the emulsifier. The coherent aqueous phase contains 2.25% glycerol and small amounts of EDTA and sodium hydroxide. In recent years, generic emulsion formulations have become available in several countries as well.
    Propofol is indicated for the induction and maintenance of general anesthesia, sedation for mechanically ventilated adults, and procedural sedation. Other clinical uses that are still experimental include the control of status epilepticus, the treatment of headache, in particular migraine headache, the control of anxiety, and neuroprotection in acute brain injury. These uses often require only sub-hypnotic doses of propofol, as taught, for example, in WO 00/54588 Al.
    Compared to other compounds used in anesthesia, propofol has a remarkable safety profile.
    Its side effects are usually mild and easily controlled. The hypnotic effect of a single dose of propofol typically wears off within minutes. The rapid onset and recovery together with its amnestic effects 30 have made the compound very popular for sedation and anesthesia.
    Unlike similar agents, it does not appear to induce nausea. Typical adverse effects include decreased blood pressure and transient apnea after induction doses. Mild myoclonic movements are commonly seen. Another frequent issue with propofol emulsion is that it produces local pain at the injection or infusion site, for which reason some patients are pretreated with a local anesthetic such as lidocaine. It is believed that the small fraction of propofol dissolved in the aqueous phase of the emulsion is responsible for your pain. Rare but more serious are dystonia, hyperlipidemia, pancreatitis and the so-called propofol infusion syndrome. This potentially lethal metabolic derangement has occurred in critically ill patients after prolonged infusion of high dose propofol in combination with catecholamines and/or corticosteroids.
    More recently, other intravenous formulations of propofol have been clinically tested or introduced to the market. For example, a 1% propofol emulsion with only 5% soy oil and 0.6% lecithin (Ampofol® has been studied.) It is likely that this formulation could be associated with a lower risk of hyperlipidemia and pancreatitis. at the same time, pain at the injection site was found to be even more severe than with Diprivan®.
    Other emulsion formulations such as Propofol-Lipuro® and IDD-D® propofol rely on a higher fraction of medium chain triglycerides (TCM) to replace long chain triglycerides (TCL) in the oil component of the emulsion. It is assumed that TCMs are better tolerated than TCLs by both adults and pediatric patients. However, they can also release toxic compounds such as acetoacetate, beta-hydroxybutyrate and octanoates.
    However, there is still some risk of hyperlipidemia and pancreatitis involved in using propofol emulsions. The relatively low drug load of these emulsions necessitates the administration of substantial amounts of triglycerides and emulsifiers (ie, phospholipids) having their own specific risk profiles.
    A further disadvantage of propofol parenteral emulsions is that they are, due to their triglyceride oil content in an aqueous environment and phospholipids as emulsifiers, prone to substantial microbial growth after contamination. Therefore, the present formulation of Diprivan® comprises (di)sodium edetate as an antimicrobial agent, although the product is limited to single patient use per vial.
    Although other microbial preservatives for injectable formulations are in principle available, they are associated with decreased tolerability and in particular with the risk of inducing hypersensitivity reactions. In WO 00/24376, benzyl alcohol alone (0.0175 - 0.9% by weight) or in combination with sodium edate (0.005% by weight) or sodium benzoate (0.07% by weight) is used for microbially stabilize an oil-in-water emulsion containing propofol, vegetable oil as a solvent, and egg phosphatides as an emulsifier.
    WO 2007/052288 describes a formulation of a propofol in the form of an oil-in-water emulsion containing triglyceride oils (5-20% w/v), 1.2% by weight of natural phosphatides such as purified soy or egg phospholipid , 2.25% by weight of glycerol as tonicity modifying agent as well as monoglyceryl esters of capric and lauric acid (0.025 - 0.05% by weight), disodium edetate (0.0025 - 0.001% by weight) and/ or capric acid (0.025 - 0.05% by weight) as preservative system. This system shows a no greater than 10-fold increase in the growth of each Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginose and Candida albicans for at least 5 24 h.
    Alternatively, non-emulsion formulations that have been suggested for propofol include aqueous solutions in which the drug substance is present in solubilized form with the aid of a cyclodextrin.
    Cyclodextrins are water-soluble cyclic oligosaccharides capable of forming inclusion complexes with guest molecules. In particular, propofol solutions with hydroxypropyl-β-cyclodextrin and with sulfobutyldter-β-cyclodextrin, respectively, were studied.
    However, it has not been established whether the pharmacokinetics of these formulations is comparable to propofol emulsions. Furthermore, high doses of cyclodextrin are often linked to hemolytic effects and renal toxicity.
    Thus, there remains a need for further improved formulations of poorly water soluble compounds like propofol. Furthermore, there is a need for improvements in the formulation of pharmaceutical emulsions. For example, there is a need for emulsions having a higher drug loading and/or a better safety profile.
    US patent no. 6,113,919 describes oil-in-water emulsions comprising an aqueous continuous phase and an oil dispersed phase, wherein the dispersed phase comprises at least two fluorinated liquids, one of which is the oils solvent or vehicle and constitutes the volume of the dispersed phase. , the second being a fluorinated co-surfactant in an amount of up to 10% w/v of the dispersed phase. The fluorinated co-surfactant is different from the fluorinated oil vehicle. The oily vehicle is a perfluorinated liquid, in particular perfluorooctyl bromide, which is used in amounts of approximately 90% w/v relative to the dispersed phase.
    However, perfluorinated compounds are quite problematic in emulsions, particularly if they are incorporated in large amounts or used as the oil phase vehicle or solvent. For example, its density is extremely high so that there is always a risk of physical phase separation through dispersed phase sedimentation, which is difficult to control. Typically, large amounts of surfactant are needed to stabilize an emulsion based on a perfluorocarbon. These emulsions are typically sensitive to mechanical stress as associated with pumping, dispensing, centrifugation, etc. furthermore, perfluorinated compounds are extremely lipophobic and hydrophobic and thus not very suitable as solvents for many active ingredients that would require at least a more moderate degree of lipophilicity and/or hydrophilicity.
    Therefore, it is an object of the present invention to provide such improved compositions that overcome one or more disadvantages of known compositions. In particular, it is an object of the invention to provide propofol compositions which exhibit high drug content and/or high microbial stability. Another objective is to provide propofol compositions that are not associated with the risk of hypolipidemia or pancreatitis. Additional objects of the invention will become clear based on the description of the invention below, including the examples, and the patent claims. SUMMARY OF THE INVENTION
    The invention provides a novel composition in the form of a physically stable, liquid oil/water emulsion comprising (a) a dispersed phase comprising a semifluorinated alkane according to the formula RFRH or RFRHRF, (b) an aqueous continuous phase, and (c) at least one surfactant, where RF is a perfluorinated hydrocarbon segment with 20 or fewer carbon atoms and RH is a non-fluorinated hydrocarbon segment with 3 to 20 carbon atoms. Perfluorinated compounds are absent in the dispersed phase. The composition is further characterized in that the average droplet size of the dispersed phase is below approximately 1 µm.
    In another aspect, the invention provides a liquid composition in the form of a physically stable O/W emulsion comprising (a) a dispersed phase comprising a semifluorinated alkane in accordance with the formula RFRH; (b) a continuous aqueous phase, and (c) at least one surfactant; where RF is a linear perfluorinated hydrocarbon segment with 4 to 12 carbon atoms, and RH is a linear alkyl group with 4 to 8 carbon atoms, again, the average dispersed phase droplet size is below approximately 1 µm.
    In one of the preferred embodiments, the dispersed phase 25 of the composition comprises a poorly water-soluble pharmaceutical active agent such as propofol. Preferably, the propofol emulsion has a high drug loading, i.e. the concentration of propofol in the dispersed phase is at least approximately 10% by weight. Preferably, the propofol composition is sterile. Due to the high antimicrobial stability of semifluorinated alkanes, the composition can be preservative-free. It is also preferably free of triglyceride oils and therefore not associated with the risk of hyperlipidemia and pancreatitis.
    In a further aspect, the invention provides a liquid O/W emulsion which is highly concentrated in which its dispersed phase represents at least approximately 50% by weight of the emulsion. Such highly concentrated versions are particularly suitable for use as pre-concentrates which can be diluted with specific aqueous liquids prior to use. Furthermore, they are useful for accommodating high amounts of water-insoluble drug substances or other hydrophobic active agents. Such emulsions can also be used for topical (e.g., dermal) administration.
    Additional aspects of the invention relate to the uses of such O/W emulsions comprising semifluorinated alkanes. For example, they can be used pharmaceutically, for example as therapeutic or diagnostic preparations. As such, they can be administered topically, orally or parenterally. In particular, emulsions comprising propofol can be used for general anesthesia and/or sedation, and can be administered by intravenous infusion or injection. Emulsions comprising an active agent useful for the preservation of tissue or organ transplants, such as N-octanoyl dopamine, can be administered to a tissue or organ transplant donor, an organ or tissue transplant recipient, and/or for lavage or soaking a tissue or organ transplant for storage or transport.
    Furthermore, the compositions of the invention can be used as cosmetic preparations or as veterinary medicines. BRIEF DESCRIPTION OF THE DRAWINGS
    Figure 1 shows the results of a test for hemolytic activity involving various compositions comprising propofol according to the invention and a propofol emulsion not according to the invention (ST174). Details are discussed in example 14.
    Figure 2 shows the results of a test for hemolytic activity in the presence of human serum, as described in more detail in example 14.
    Figure 3 shows the sedative efficacy of a propofol emulsion according to the invention compared to a conventional propofol product determined in a rat model as described in example 15.
    Figure 4 shows the plasma profiles of propofol in rats after intravenous bolus administration of a propofol emulsion according to the invention compared to a conventional propofol product as described in example 16. DETAILED DESCRIPTION OF THE INVENTION
    The invention provides a novel composition in the form of a physically stable liquid O/W emulsion comprising (a) a dispersed phase comprising a semifluorinated alkane according to the formula RFRH or RFRHRF, (b) an aqueous continuous phase, and (c) at least one surfactant, where RF is a perfluorinated hydrocarbon segment having 20 or fewer carbon atoms and RH is a non-fluorinated hydrocarbon segment having 3 to 20 carbon atoms. Perfluorinated compounds are absent in the dispersed phase. The composition is further characterized in that the average droplet size of the dispersed phase is below approximately 1 µm.
    In another aspect, the invention provides a liquid composition in the form of a physically stable O/W emulsion comprising (a) a dispersed phase comprising a semifluorinated alkane in accordance with the formula RFRH; (b) a continuous aqueous phase, and (c) at least one surfactant; where RF is a linear perfluorinated hydrocarbon segment having 4 to 12 carbon atoms, and RH is a linear alkyl group having 4 to 8 carbon atoms. Again, the average dispersed phase droplet size is below approximately 1 µm.
    As used herein, an emulsion is a liquid system comprising a dispersed (or internal, or emulsified or discontinuous) liquid phase in a continuous (or external or coherent) liquid phase. The two liquid phases are not miscible. In an O/W emulsion (also referred to as an oil-in-water emulsion), a water-immiscible organic liquid phase, which does not have to be an "oil" by any specific definition, is dispersed into a water-miscible continuous phase that can or not be substantially comprised of the water itself.
    Semifluorinated alkanes are linear or branched alkanes some of whose hydrogen atoms have been replaced by fluorine. In a preferred embodiment, the semi-fluorinated alkanes (ASFs) used in the present invention are composed of at least one non-fluorinated hydrocarbon segment and at least one perfluorinated hydrocarbon segment. Particularly useful are ASFs which have a non-fluorinated hydrocarbon segment bonded to a perfluorinated hydrocarbon segment in accordance with the general formula F(CF2)n(CH2)mH or two perfluorinated hydrocarbon segments separated by a non-fluorinated hydrocarbon segment, according to the general formula F(CF2)n(CH2)in(CF2)oF.
    Another nomenclature that is used here refers to the aforementioned ASFs having two or three segments such as RFRH and RFRHRF, respectively, where RP designates a perfluorinated hydrocarbon segment, RH designates a non-fluorinated segment. Alternatively, the compounds may be mentioned as FnHm and FnHmFo, respectively, where F stands for a perfluorinated hydrocarbon segment, H for a non-fluorinated segment, and n, m and o is the number of carbon atoms of the respective segment. For example, 5 F3H3 is used for perfluoropropylpropane. Furthermore, this type of nomenclature is commonly used for compounds having linear segments. Therefore, unless otherwise indicated, it should be assumed that F3H3 means 1-perfluoropropylpropane, rather than perfluoropropylpropane, 1-perfluoroisopropyl propane or 2-perfluoroisopropyl propane.
    Preferably, the semifluorinated alkanes according to the general formulas F(CF2)n(CH2)fflH and F(CF2)n(CH2)m(CF2)OF have segment sizes ranging from 15 to 20 carbon atoms, i.e. is, n, m, and o are independently selected in the range of 3 to 20. ASFs which are useful in the context of the present invention are also described in EP-A 965 334, EP-A 965329 and EP-A 2110126, the disclosure of which documents are incorporated here.
    In an additional modality, the semifluorinated alkane is a compound according to the formula RFRH, whose RF and RH segments are linear and each - but independently of each other - has from 3 to 20 carbon atoms. In another specific embodiment, the perfluorinated segment is linear and comprises 4 to 12 carbon atoms, and/or the non-fluorinated segment is linear and comprises 4 to 8 carbon atoms. Preferred ASFs include in particular the compounds F4H5, F4H6, F4H8, F6H4, F6H6 and F6H10. Currently most preferred for carrying out the invention are F4H5, F4H6, F4H8, F6H6 and F6H8.
    Optionally, the dispersed phase of the emulsion can comprise more than one ASF. It may be useful to combine ASFs, for example, to obtain a specific target property such as a certain density, viscosity or solubilization capacity for a specific active ingredient. If a mixture of ASFs is used, it is further preferred that the mixture comprises at least one of F4H5, F4H6, F6H4, F6H6, F6H8 and F6H10, and in particular one of F4H5, F4H6, F6H6 and F6H8. In another embodiment, the mixture comprises at least two elements selected from F4H5, F4H6, F6H4, F6H6, F6H8 and F6H10, and in particular at least two elements selected from F4H5, F6H6 and F6H8. In some preferred embodiments, perfluorinated compounds are absent.
    Liquid ASFs are chemically and physiologically inert, colorless and stable. Their typical densities range from 1.1 to 1.7 g/cm3 and their surface tension can be as low as 19 mN/m. RFRH-type ASFs are insoluble in water but also somewhat amphiphilic, with increasing lipophilicity correlating with an increasing size of the non-fluorinated segment. Again, to practice the present invention, an ASF having a density of at least 1.2 g/cm3 must be selected.
    RFRH-type liquid ASFs are being used commercially to expose and reapply a retina for long-term tamponade as a vitreous humor substitute (H. Meinert et al., European Journal of Ophthalmology, vol. 10(3), pp. 189-197 , 2000), and as washout solutions for residual silicon oil after vitreous-retinol surgery. Experimentally, they have also been used as blood substitutes (H. Meinert et al., Biomaterials, Artificial Cells, and Immobilization. Biotechnology, vol. 21(5), pp. 583-95, 1993). These applications have stabilized ASFs as physiologically well-tolerated compounds. On the other hand, ASFs have not been used as excipients in today's approved drug products.
    The dispersed phase of the emulsion may comprise other constituents, such as one or more organic diluents (eg, triglyceride oils), osmotic stabilizers, coloring agents, antioxidants (eg, a-tocopherol), or another potentially useful compound in view of intended use of the product or incorporated active ingredient, if any. On the other hand, the dispersed phase preferably does not comprise perfluorinated compound such as perfluorooctyl bromide or perfluorodecalin.
    The composition further comprises a surfactant. Although semifluorinated alkanes exhibit some degree of amphiphilicity, the composition of the invention requires the presence of a surfactant other than a semifluorinated alkane. The surfactant is selected and incorporated in an amount capable of physically stabilizing the emulsion. The surfactant is believed to be present at the interface of the dispersed liquid droplets and the continuous phase and, optionally, in the continuous phase itself.
    Preferably, the surfactant is physiologically acceptable in view of the intended purpose and route of administration. In one of the preferred embodiments, at least one surfactant having an HLB value of 8 or higher is incorporated. In a further embodiment, an incorporated surfactant has an HLB value of approximately 12 or higher, or approximately 14 or higher. As used herein, the HLB value refers to the hydrophilic-lipophilic balance commonly used to describe the degree to which an amphiphilic molecule as a surfactant is hydrophilic or lipophilic. The HLB value can be calculated based on the relative size of the different regions of the molecule, as originally proposed by W. Griffin (Classification of surface-active agents by 'HLB';
    Journal of the Society of Cosmetic Chemists 1, 311, 1949).
    The surfactant can be ionic or non-ionic. In a specific embodiment, the composition comprises an ionic surfactant preferably selected from the class of phospholipids. Phospholipids are surfactants composed of a phosphate group (which carries a negative charge) which is, on the one hand, attached to a small basic residue (usually carrying a positive charge) such as choline or ethanol amine, and on the other hand glycerol or 10 sphingosine. The glycerol residue is esterified with two fatty acid residues which represent the lipophilic part of the phospholipid molecules.
    Among the preferred phospholipids are native, hydrated and/or purified lecithins, such as lecithin derived from eggs or soy, typically comprising high amounts of phosphatidyl cholines. Native, purified, synthetic or semi-synthetic phosphatidyl cholines having mixed fatty acid residues as found in their native sources or generated by hydration are also preferred; or specific fatty acid compositions such as, for example, dimyristoyl phosphatidyl choline, dipalmitoyl phosphatidyl choline and distearoyl phosphatidyl choline. Furthermore, phospholipids extracted from animal organs such as lungs can be used, for example, pulmonary phospholipids from pigs, as comprised in the product, Curosurf®. Particularly preferred surfactants are purified and optionally hydrated lecithins extracted from eggs or soy.
    In an alternative preferred embodiment, the surfactant is selected from the class of physiologically acceptable nonionic surfactants. Examples for such surfactants include in particular: pegylated glycerides such as macrogol-15-hydroxy stearate (for example Solutol® HS 15), macrogol glycerol ricinoleate-35 (for example Cremophor® EL), macrogol glycerol hydroxystearate-40 (for example example, Cremophorf® RH 40), macrogol-1000-glycerol monolaurate, macrogol-1000-glycerol monostearate, and macrogol-1000-glycerol monooleate; - pegylated fatty acids such as macrogol stearate 400, polyoxyl 40 stearate and polyoxyl 60 stearate; - pegylated fatty alcohols such as macrogol lauryl ether, polyoxyl 20 cetostearyl ether and polyoxyl 10 oleyl ether; - pegylated sorbitan fatty acid esters such as polysorbate 20, polysorbate 40, polysorbate 60 and polysorbate 80 (for example Tween® 20/40/60/80); and - polyoxyethylene and polyoxypropylene triblock copolymers, such as poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338, and poloxamer 407. From the above, polysorbates are particularly preferred.
    It is also possible to incorporate more than one surfactant in the composition of the invention. For example, the combination of an ionic surfactant such as lecithin and a non-ionic surfactant such as polysorbate or poloxamer can be useful to stabilize the emulsion if the continuous phase comprises substantial amounts of salts or other electrolytes.
    In a further embodiment, a nonionic surfactant is selected as a single surfactant in a composition comprising sodium chloride or another salt in the continuous phase of the emulsion. In another embodiment, an ionic surfactant such as lecithin or phosphatidyl choline is selected as the sole surfactant, and the continuous phase of the emulsion is substantially free of salts such as sodium chloride. If an osmotic agent is required in that case, such an agent is preferably selected from physiologically acceptable non-ionic osmotic agents such as sugars (eg glucose) or sugar alcohols (such as mannitol or sorbitol).
    It has been discovered by the inventors that, based on the guidance given above regarding the selection of dispersed phase, continuous phase and surfactant components, emulsion systems can be prepared by common emulsification systems that are physically stable. In this context, physically stable means stable against major changes in the emulsion droplet size distribution and in particular against coalescence. Preferably, physical stability includes resistance to substantial particle size growth even under heating, for example, at temperatures at which the emulsion is pasteurized or even sterilized. Contrary to the teachings of the prior art, the inventors have thus discovered O/W emulsions comprising semifluorinated alkanes which are heat sterilizable even in the presence of salts. As used herein, substantial particle size growth is understood to mean an increase in the average droplet size of the emulsion from a starting value to more than approximately 150% of that value.
    The average droplet size of the composition of the invention is understood as the z-average droplet size as measured by laser diffraction or dynamic light scattering. It is less than approximately 1 µm, but depending on the specific application of the product, it can also be selected to be less than approximately 500 nm, as preferred if the composition is intended for intravenous infusion or injection. According to further embodiments, the average droplet size is up to approximately 400 nm, or up to approximately 300 nm, or from approximately 150 nm to approximately 400 nm, respectively.
    Emulsions based on semifluorinated alkanes having such average droplet sizes can be prepared by generally known techniques with or without adaptation. For example, the components of the emulsion can be combined and emulsified by high shear homogenization, high pressure homogenization, ultrasonic homogenization, static mixing and the like. It is recommended first to prepare, separately, the hydrophilic and lipophilic solutions that will constitute the dispersed and continuous phases of the O/W emulsion, respectively. The surfactant(s) and optionally any additional hydrophilic additives can be dissolved in a suitable vehicle for the continuous phase, such as water or aqueous buffer. Similarly, the components for the dispersed phase, i.e. the selected semifluorinated alkane(s), together with any additional optional compound such as lipophilic or hydrophobic drug substance, can be provided as a solution. Subsequently, the two solutions can be mixed and homogenized until the desired droplet size distribution is obtained. Optionally, the mixture is cooled during homogenization.
    The emulsion can be filled into vials or any other suitable containers. If a sterile emulsion is required, the emulsion can be prepared from sterile constituents by aseptic processing. Alternatively, the emulsion can be sterilized by filtration through a suitable filter, having, for example, a pore size of approximately 0.2 µm. in one of the preferred embodiments, the emulsion is heat sterilized, for example, by applying a pasteurization process, and more preferably by autoclaving, for example, at 121°C. It is one of the specific advantages of the present invention that it provides emulsions that are physically stable not only at room temperature, but also at elevated temperatures such as during autoclaving. Indeed, according to one of the preferred embodiments, the composition of the invention is sterile, or heat sterilizable.
    Although sterility is an important requirement in the context of certain product applications, in particular for products for parenteral or ophthalmic administration, it can also be of great importance in ensuring that the product does not lose its microbial purity during use. For example, the US Food and Drug Administration (FDA) and Center for Disease Control (CDC) require that any microbial growth in the 24-hour time period after opening a sterile container for immediate parenteral use be less than 10 times the contents. . Unexpectedly, it was discovered by the inventors that emulsions as provided by the invention do not support microbial growth as, for example, conventional emulsions comprising triglyceride oils do. Resistance to microbial growth is further enhanced in cases where a lecithin (which also tends to support microbial growth) is used as an emulsifier. Therefore, in one of the preferred embodiments, the composition of the invention is substantially free of any preservatives. In another embodiment, the composition comprises a small amount of preservative, but at a level that would not prevent microbial growth in the absence of a semifluorinated alkane.
    The content of dispersed phase in the composition will depend on the intended product use. For example, it can range from approximately 1 to approximately 80% by weight. the excellent physiological tolerability of semifluorinated alkanes and the high physical stability obtained by the emulsions of the invention allow the preparation and use of compositions with surprisingly high amounts of dispersed phase, in particular 50% by weight and more, or even higher than 60% by weight. weight such as approximately 60% on. weight to approximately 80% by weight. Such highly concentrated emulsions are particularly suitable to be used as pre-concentrates which can be diluted with specific aqueous liquids before use. Furthermore, they are useful for accommodating high amounts of water-insoluble drug substances or other hydrophobic active agents. Such emulsions can also be used for topical (for example, dermal) administration.
    The present invention is particularly useful as a human or veterinary medicine. The dispersed phase of the emulsion based on a semifluorinated alkane is a highly suitable vehicle for poorly water-soluble, or hydrophobic or lipophilic active pharmaceutical ingredients. In one of the preferred embodiments, the composition comprises at least such active ingredient in dissolved form in the dispersed phase.
    As used herein, an active pharmaceutical ingredient is a compound or mixture of compounds useful in the diagnosis, prevention, control and/or therapy of a human or animal condition or disease. It may also be referred to as active ingredient, active agent, active compound, drug substance and the like.
    Again, the active ingredient incorporated in the composition is preferably sparingly soluble in water. In particular, the solubility in water is preferably not greater than approximately 1 mg/ml. In other preferred embodiments, the water solubility is not higher than approximately 0.1 mg/ml, or no more than approximately 10 µg/ml, respectively. The invention is particularly useful for providing such active ingredients because it allows the administration of effective doses in relatively small volumes, which is partly due to the surprisingly high solubilization capacity of semifluorinated alkanes for many poorly water-soluble drug substances, but also a beneficial effect. the high physical stability of the emulsions which allows the formulation of compositions comprising large amounts of dispersed phase.
    In a specific embodiment, the composition comprises a poorly water-soluble active ingredient selected from the class of general anesthetic agents, which includes candidate compounds such as propofol and etomidate. Particularly preferred is propofol, also known as 2,6-diisopropylphenol, whose properties and uses have already been described above.
    The inventors surprisingly found that semifluorinated alkanes have a remarkable ability to solubilize propofol. In fact, propofol is fully miscible with certain highly preferred semifluorinated alkanes, such as F4H5, F4H6 and F6H8, over a wide temperature range, in others it has very high solubility. Although it was previously suggested that semifluorinated alkanes might be useful solvents for certain lipophilic compounds, this extraordinary level of solubilization capacity might not have been predicted for propofol. Due to the high solubility of propofol in semifluorinated alkanes, it is now possible to provide injectable propofol formulations having high strength (or concentration of propofol), and thus requiring only a low volume of administration. This will also lead to improved tolerability, as a lower administration volume inherently means a lower intake of excipients (such as emulsifiers). Furthermore, these compositions are free of triglyceride oils and therefore do not have the disadvantages associated with triglycerides, including the risk of hyperlipidemia and pancreatitis.
    Preferred semifluorinated alkanes for formulating propofol emulsions according to the invention include in particular the compounds F4H5, F4H6, F6H4, F6H6, F6H8 and F6H10. Currently, F4H5, F4H6, and D6H8 are most preferred. Optionally, the composition can comprise more than one ASF. It may be useful to combine ASFs, for example, to obtain a specific target property such as a certain density or viscosity. If a mixture of ASFs is used, it is further preferred that the mixture comprises at least one of F4H5, D4H6, F6H6, F6H8 and F6H10, and in particular one of F4H5, F4H6 and F6H8. In another embodiment, the mixture comprises at least two elements selected from F4H5, F4H6, F6H4, F6H6, F6H8 and F6H10, and in particular at least two elements selected from F4H5, F4H6 and F6H8.
    To allow safe and convenient dosing and administration, the composition of the invention should have a strength (i.e., concentration of propofol) in the range of approximately 0.1% by weight to approximately 50% by weight. In additional embodiments, the strength is approximately 1% by weight or higher, such as at least approximately 2% by weight, 5% by weight, 10% by weight or 20% by weight, the concentration of propofol in the dispersed phase may vary from 1% by weight to 99% by weight, in specific embodiments, the dispersed phase contains approximately 10-50% by weight of propofol dissolved in semifluorinated alkane(s), such as approximately 10% by weight, 20% by weight, 30% by weight, 40% by weight, or 50% by weight, respectively.
    The emulsifier is preferably a compound with proven safety for parenteral use. In certain embodiments, the emulsifier is selected as described above in the context of semifluorinated alkane based emulsions according to the invention in general. In other specific modalities, the emulsifier is selected from lecithins, phosphatidyl cholines, polysorbates and poloxamers. The amount of surfactant is selected in consideration of the amount of dispersed phase in the emulsion. It can range, for example, from approximately 0.5% by weight to approximately 100% by weight relative to the weight of the dispersed phase. In additional embodiments, the surfactant is present in an amount ranging from approximately 2% by weight to approximately 50% by weight relative to the dispersed phase, or from approximately 2% by weight to approximately 20% by weight, or from approximately 4% by weight to approximately 10% by weight, respectively. In case more than one. surfactant is used, the percentages refer to the total amount of surfactant.
    Propofol emulsions may contain additional excipients, in particular in the continuous phase which is preferably water based. For example, it is preferred that an excipient or excipient blend be incorporated to ensure that the osmotic pressure of the composition is in the physiologically acceptable range, such as in the range of approximately 200 to approximately 500 mOsmol/kg, or more preferably in the range of approximately 250 at approximately 400 mOsmol/kg, or from approximately 280 to approximately 350 mOsmol/kg, respectively. Osmolality can be adjusted with commonly used excipients that are physiologically acceptable such as sodium chloride, sugars such as glucose, sugar alcohols such as mannitol or sorbitol, and the like. In case sodium chloride or other salts are used for this purpose, the surfactant or, if more than one surfactant is used, at least one of the surfactants must be selected from the 10 class of non-ionic surfactants.
    In a further preferred embodiment, one or more excipients are incorporated to maintain the pH of the propofol composition within a physiologically acceptable range. In particular, the pH of the composition can be adjusted to pH 4 15 to pH 9, or more preferably in the range of pH 5 to pH 8, such as from pH 6 to pH 7.5. To adjust and optionally buffer the pH value, physiologically acceptable acids, bases, salts and combinations thereof can be used. Suitable excipients for lowering the pH value or as acidic components of a buffer system are strong mineral acids, in particular sulfuric acid and hydrochloric acid. In addition, medium strength inorganic and organic acids as well as acidic salts can be used, for example, phosphoric acid, citric acid, tartaric acid, succinic acid, fumaric acid, methionine, acidic hydrogen phosphates with sodium or potassium, lactic acid , glucuronic acid, etc.
    However, sulfuric acid and hydrochloric acid are more preferred. Suitable for raising the pH value or 30 as a basic component for a buffer system, in particular, mineral bases such as sodium hydroxide or other alkaline and alkaline earth hydroxides and oxides, such as, in particular, magnesium hydroxide and calcium hydroxide, ammonium hydroxide and basic ammonium salts such as ammonium acetate, as well as basic amino acids such as lysine, carbonates such as magnesium or sodium carbonate, sodium hydrogen carbonate, citrates such as sodium citrate, etc. In addition, readily available buffered aqueous isotonic solutions can be used as the basis for continuous phase preparation.
    The propofol emulsions according to the invention can be used in the same way and for the same purposes as conventional propofol compositions, i.e. for the induction and maintenance of general anesthesia or for sedation. The compositions are preferably supplied in sterile form and injected or infused intravenously.
    In a further embodiment, the composition of the invention is provided as an emulsion having high dispersed phase content, such as approximately 40% by weight or more, or approximately 50% by weight or more, or preferably at least approximately 60% by weight or more. approximately 60% by weight to less than approximately 80% by weight. weight, respectively, and adapted for use as a pre-concentrate to be diluted with an aqueous organ preservation solution such as HTK (histidine-tryptophan-ketoglutarate) solution or UW (University of Wisconsin) solution. Semifluorinated alkanes have a high capacity to dissolve and carry oxygen, which makes these compounds highly attractive for organ or tissue preservation. Although semifluorinated alkanes per se are not miscible with conventional aqueous organ preservation solutions, the emulsions provided by the invention are physically highly stable and compatible with such solutions. They can be easily and conveniently diluted with these prior to use in order to combine the beneficial effects of semifluorinated alkanes with those of conventional organ preservation solutions. Of course, it is also possible to incorporate an active pharmaceutical ingredient into a concentrated emulsion intended for tissue or organ preservation.
    Such composition is preferably sterile and adapted for parenteral administration. It can be administered, in particular after dilution, systemically or locally to a transplant donor for pre-treatment and prevention of ischemic damage, or used in vitro to wash and preserve allografts to minimize cold preservation injury.
    Other active ingredients and product applications are also considered. For example, the composition may comprise a poorly water-soluble active ingredient useful for the prevention or therapy of a skin or mucosal disease or condition, and adapted for topical, e.g., dermal or mucosal (including buccal and sublingual) administration. . Even without the incorporation of any specific active pharmaceutical ingredient, the composition can be used for cosmetic purposes as it has been found to have excellent skin tolerability and good dispersing behavior.
    The invention is further illustrated by the following examples which are not intended to limit the scope of the invention. EXAMPLES
    Example 1 of propofol was dissolved in 10 g of F6H8. This mixture was added to a solution of 800 mg S75 (soy lecithin, Lipoid AG) in 979.2 g of aqueous dextrose solution (5% by weight) in water and stirred for 1 h at 2000 rpm. The emulsion was then prepared by high pressure homogenization process using an Avestin C3 apparatus at a pressure of 1100 bar in continuous process for 1 hour, the pH value was adjusted to pH 7.3 - 7.5 by adding hydroxide solution of sodium. The final emulsion was placed in vials, closed and sealed after covering with nitrogen. Subsequently, the vials were sterilized at 121°C for 10 minutes.
    The average droplet size was 212 nm. Surprisingly, during the first 6 months of storage at 23°C, the average droplet size showed no significant increase. From this batch, 20 vials were tested according to Ph. Eur. 6 and found to be sterile.
    Example 2 0.1 g of propofol was dissolved in 0.1 g of F6H8. This mixture was added to a solution of 16 mg of S75 in 9.784 g of dextrose solution (5% by weight) in water and stirred for 1 h at 2000 rpm. The emulsion was formed by ultrasonication of the pre-emulsion for 240 s (1 s pulse, 1 s interval) at 100% amplitude (Hilcher sonicator, 1/4 inch tip) under ice cooling. The pH value was adjusted to pH 7.3 - 7.5 by adding sodium hydroxide solution. The final emulsion was placed in vials, closed and sealed after covering with nitrogen. Subsequently, the vials were sterilized at 121°C for 10 minutes.
    Example 3 Essentially the same way as in example 2, a sterilized emulsion was prepared from 0.1 g propofol, 0.5 g F6H8, and a solution of 80 mg S75 in 9.72 g dextrose solution (5 % by weight).
    Example 4 Essentially the same way as in example 2, a sterilized emulsion was prepared from 0.2 g propofol, 0.2 g F6H8, and a solution of 32 mg S75 in 9.568 g dextrose solution (5% in weight) containing HEPES (10 mmol/L).
    Example 5 Essentially in the same way as in example 2, a sterilized emulsion was prepared from 1 g propofol, 1 g F6H8, and a solution of 160 mg S75 in 7.84 g dextrose solution (5% by weight) .
    Example 6 Essentially the same way as in example 2, a sterilized emulsion was prepared from 0.1 g propofol, 0.3 g F6H8, and a solution of 16 mg S75 in 9.784 g dextrose solution (5% in Weight).
    Example 7 Essentially in the same way as in example 2, a sterilized emulsion was prepared from 0.1 g of propofol, 0.8 g of F6H8, 0.2 g of olive oil (Sigma Aldrich) and a solution of 8 mg of S75 in 9,792 g of dextrose solution (5% by weight).
    Example 8 Essentially in the same way as in example 2, a sterilized emulsion was prepared from 0.1 g of propofol, 0.1 g of F6H8, and a solution of 8 mg of S75 and 8 mg of sodium oleate in 9.784 g of dextrose solution (5% by weight).
    Example 9 Essentially in the same way as in example 2, a sterilized emulsion was prepared from 0.2 g of propofol, 0.2 g of F6H8, and a solution of 32 mg of S75 and 8 mg of sodium oleate in 9.568 g of dextrose solution (5% by weight).
    Example 10 Essentially in the same way as in example 2, a sterilized emulsion was prepared from 0.1 g of propofol, 0.067 g of F6H8, 0.033 g of F4H5 and a solution of 16 mg of epcs (Lipoid ag) in 9.784 g of solution of dextrose (5% by weight).
    Example 11 Essentially the same as in example 1, except that additionally 3 mg of the Patent Blue V dye was used, a sterilized blue emulsion was prepared.
    Example 12 Essentially in the same way as in example 2, a sterilized emulsion was prepared from 0.1 g propofol, 0.01 g α-tocopherol, 0.1 g F6H8, and a solution of 8 mg S75 in 9,792 g of dextrose solution (5% by weight).
    Example 13 An antimicrobial preservative efficacy test in analogy to that of USP 32 <51> was performed. Sample vials prepared according to examples 1, 3 and 4 were inoculated with Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Candida albicans and Aspergillus Niger and incubated at approximately 22.5°C. commercially obtained samples of Disoprivan® were tested as comparators. The results are given in Tables 1 to 4. Surprisingly, no increase but a substantial decrease in the concentration of colony forming units (cfu) over 24 and 48 hours was observed in the case of emulsions comprising semifluorinated alkanes. Obviously, the emulsions according to the invention do not support microbial growth, but instead inhibit it in the same way as if an effective amount of an antimicrobial preservative had been added. In contrast, Disoprivan® samples showed a marked increase in cfu/ml for Escherichia coli, Staphylococcus aureus and Candida albicans. Table 1

    To determine whether the observed inhibition of microbial growth in the emulsions of the invention is an effect of semifluorinated alkanes or propofol, the test was repeated with a placebo emulsion containing no propofol but only F6H8 at a higher concentration (40% by weight) and S75 in dextrose solution. Pure solutions of F6H8 and F4H5 were also tested. The results are given in Table 5 to 7 and indicate that this propofol-free emulsion is also able to reduce the concentration of
    Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus. In the case of Aspergillus Niger, an initial decrease in cfu concentration was obtained, but after 48 hours it was back to the starting level. Only Candida albicans concentrations increased substantially, probably due to the presence of lecithin. Table 5


    Example 14 Emulsions were prepared essentially as in example 2 and tested for their hemolytic effects on human erythrocytes in the presence and absence of human serum. The continuous phase of the emulsions consisted of aqueous glucose solution (5% by weight), the other constituents of the emulsions are given in table 8. In summary, aliquots of a suspension of human erythrocytes in phosphate buffered saline were mixed with aliquots. of the test samples and the comparator in microtiter plates and further diluted in steps to obtain a dilution series down to a dilution factor of 256. As a positive control, an analogous dilution series of the erythrocyte suspension with buffer was prepared wherein the erythrocytes were subsequently completely lysed using a surfactant solution. For each dilution, the degree of hemolysis was quantified by measuring the optical density of hemoglobin by spectrophotometry.
    As a result, it was found that, in the absence of serum, only the emulsion prepared from propofol without semifluorinated alkanes (ST174) caused significant concentration-dependent hemolysis. All other emulsion compositions showed no or only negligible hemolysis, regardless of concentration (see Figure 1). In the presence of serum, the propofol emulsion without semifluorinated alkanes (ST174) again caused significant concentration-dependent hemolysis, whereas the two tested emulsions comprising semifluorinated alkanes (ST245, ST311) showed no hemolysis. Disoprivan® was also tested this time and showed some moderate degree of hemolysis (see figure 2). Table 8
    Percent of S75 refers to the weight of the dispersed phase; all other percentages refer to the total emulsion
    These results demonstrate that propofol emulsions based on semifluorinated alkanes as provided according to the invention show excellent blood compatibility which should correspond to a superior tolerability profile. This is despite the fact that propofol itself shows poor compatibility with erythrocytes and leads to significant hemolysis. Apparently, the content of semifluorinated alkanes in the compositions of the invention provides protection against hemolysis.
    Example 15 The sedation efficacy of a propofol emulsion with F6H8 having a strength of 1% by weight (batch code ST245, see table 8) was compared with that of Disoprivan® in a rat sedation model. In summary, the following parameters were observed and recorded together with the time of occurrence after iv injection of a dose corresponding to 10 mg of propofol per kg of body weight of each formulation: loss of righting reflex (ta), loss of reaction to toe squeezing (ie, pain) stimulus (Tb), onset of excitation phase (tex), retrieval of straightening reflex (trr). As a result, the same effects occur at similar times after injection, and some minor differences between Disoprivan® and the emulsion under test with regard to the onset of the excitation phase and re-obtaining the straightening reflex were not statistically significant (see figure 3) .
    Example 16 The pharmacokinetics after intravenous injection of a propofol emulsion comprising F6H8 having a propofol strength of 1% by weight (batch code ST129, see table 8) in Wistar rats was compared with that of Disoprivan®. As shown in Figure 4, the plasma concentration profiles were very similar for the two formulations with some minor differences from the maximum plasma concentrations, indicating that the test emulsion can be used in a similar way as Disoprivan®, without requiring dose adjustments.
    权利要求:
    Claims (15)
    [0001]
    1. Liquid composition in the form of a physically stable O/W emulsion comprising: (a) a dispersed phase comprising a semifluorinated alkane according to the formula: RFRH; (b) a continuous aqueous phase; and (c) at least one surfactant; characterized by the fact that: RF is a linear perfluorinated hydrocarbon segment with 4 to 12 carbon atoms, RH is a linear alkyl group with 4 to 8 carbon atoms, and in which the average dispersed phase droplet size is less than 1 µm.
    [0002]
    2. Composition according to claim 1, characterized in that the semifluorinated alkane is selected from F4H5, F4H6, F4H8, F6H6 and F6H8.
    [0003]
    3. Composition according to any one of the preceding claims, further characterized in that it is sterile and/or heat sterilizable.
    [0004]
    4. Composition, according to any one of the preceding claims, characterized in that it comprises a non-ionic surfactant and additionally the aqueous continuous phase comprises a salt or ionic compound.
    [0005]
    5. Composition according to any one of claims 1 to 3, characterized in that it comprises an ionic surfactant and additionally the aqueous continuous phase comprises a physiologically acceptable non-ionic osmotic agent.
    [0006]
    6. Composition according to any one of the preceding claims, characterized in that the continuous aqueous phase comprises a compound selected from buffers and amino acids.
    [0007]
    7. Composition according to any one of the preceding claims, characterized in that the dispersed phase comprises an active pharmaceutical ingredient.
    [0008]
    Composition according to any one of the preceding claims, characterized in that the dispersed phase comprises one or more of an organic diluent, an osmotic stabilizer, a coloring agent or an antioxidant.
    [0009]
    9. Composition according to claim 7, characterized in that the active pharmaceutical ingredient is propofol.
    [0010]
    10. Composition according to claim 9, characterized in that the concentration of propofol in the dispersed phase is at least 10% by weight.
    [0011]
    Composition according to any one of claims 9 or 10, characterized in that it is for use in inducing and/or maintaining anesthesia, or for sedation, the use comprising the parenteral administration of the composition to a patient in need thereof.
    [0012]
    12. Composition according to any one of the preceding claims, characterized in that the dispersed phase represents at least 50% by weight of the emulsion.
    [0013]
    Composition according to any one of claims 1 to 10, characterized in that it is for use as a medicine.
    [0014]
    14. Composition according to claim 13, characterized in that the drug is a drug administered topically.
    [0015]
    Use of a composition as defined in any one of claims 1 to 8, characterized in that it is as a means for the preservation and/or storage and/or transport of an organ transplant.
    类似技术:
    公开号 | 公开日 | 专利标题
    US20200360285A1|2020-11-19|O/w-emulsions comprising semifluorinated alkanes
    US7915317B2|2011-03-29|Aqueous 2,6-diisopropylphenol pharmaceutical compositions
    JP5668004B2|2015-02-12|Aqueous pharmaceutical composition of 2,6-diisopropylphenol | and use thereof
    US6726919B2|2004-04-27|Injectable dispersion of propofol
    BR112012027279B1|2020-12-29|low oil pharmaceutical emulsion compositions comprising progestogen
    BR112013023458B1|2020-04-07|ophthalmic composition, and method for making the ophthalmic composition
    US20100130619A1|2010-05-27|Pharmaceutical composition for parenteral administration of idebenone
    PT2197492E|2012-02-20|Novel taxoid-based compositions
    WO2019123221A1|2019-06-27|Pharmaceutical composition comprising clevidipine and process for preparation thereof
    同族专利:
    公开号 | 公开日
    AU2012204932A1|2013-07-04|
    MX353154B|2017-12-20|
    CA2819988A1|2012-07-12|
    MX2013007807A|2013-12-16|
    CN103313729B|2016-11-09|
    EP2661280B1|2018-11-21|
    EP3202421B1|2018-03-28|
    AU2012204932B2|2017-02-23|
    DK3202421T3|2018-07-16|
    PT3202421T|2018-07-03|
    PL2661280T3|2019-05-31|
    WO2012093113A1|2012-07-12|
    TR201808752T4|2018-07-23|
    US20200360285A1|2020-11-19|
    CA2819988C|2019-11-12|
    US20170216204A1|2017-08-03|
    EP2661280A1|2013-11-13|
    CN103313729A|2013-09-18|
    PL3202421T3|2018-10-31|
    EP3202421A1|2017-08-09|
    ES2675242T3|2018-07-09|
    TR201901309T4|2019-02-21|
    JP2014501270A|2014-01-20|
    ES2711760T3|2019-05-07|
    DK2661280T3|2019-03-04|
    KR101910213B1|2018-12-19|
    US20190224123A1|2019-07-25|
    JP6073244B2|2017-02-01|
    US20140004197A1|2014-01-02|
    KR20140003477A|2014-01-09|
    PT2661280T|2019-02-25|
    BR112013016661A2|2016-10-04|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US5077036A|1986-01-14|1991-12-31|Alliance Pharmaceutical Corp.|Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid|
    FR2679150B1|1991-07-17|1994-04-22|Atta|
    DE19536504C2|1995-09-29|1999-09-23|H Meinert|Use of fluorinated alkanes|
    DE19709704C2|1997-03-10|1999-11-04|Michael Georgieff|Use of a liquid preparation of xenon for intravenous administration when inducing and / or maintaining anesthesia|
    AT252889T|1998-08-19|2003-11-15|Skyepharma Canada Inc|INJECTABLE AQUEOUS PROPOFOL DISPERSIONS|
    US6140374A|1998-10-23|2000-10-31|Abbott Laboratories|Propofol composition|
    WO2000054588A1|1999-03-15|2000-09-21|John Claude Krusz|Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages|
    US6177477B1|1999-03-24|2001-01-23|American Home Products Corporation|Propofol formulation containing TRIS|
    US6399087B1|2000-12-20|2002-06-04|Amphastar Pharmaceuticals, Inc.|Propofol formulation with enhanced microbial inhibition|
    CA2446060A1|2001-05-07|2002-11-14|Corium International|Compositions and delivery systems for administration of a local anesthetic agent|
    CA2540621A1|2003-11-19|2005-06-09|Barnes-Jewish Hospital|Enhanced drug delivery|
    AT420625T|2005-08-05|2009-01-15|Bharat Serums & Vaccines Ltd|INTRAVENOUS PROPOFOL EMULSION COMPOSITIONS WITH CONSERVATIVE EFFECT|
    TWI376239B|2006-02-01|2012-11-11|Andrew Xian Chen|Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof|
    ES2377152T3|2008-04-18|2012-03-22|Novaliq Gmbh|Inhalative and instillative use of semi-fluorinated alkanes as vehicles of active ingredients in the intrapulmonary region|WO2011113855A2|2010-03-17|2011-09-22|Novaliq Gmbh|Pharmaceutical composition for treatment of increased intraocular pressure|
    EP2444063A1|2010-10-20|2012-04-25|Novaliq GmbH|Liquid pharmaceutical compositions for the delivery of active ingredients|
    EP2462921A1|2010-11-11|2012-06-13|Novaliq GmbH|Liquid pharmaceutical compositions for the treatment of a posterior eye disease|
    EP2714010B1|2011-05-25|2017-03-01|Novaliq GmbH|Topical pharmaceutical composition based on semifluorinated alkanes|
    JP6023181B2|2011-05-25|2016-11-09|ノバリック ゲーエムベーハー|Pharmaceutical composition for administration to the nail|
    JP6084987B2|2012-01-23|2017-02-22|ノバリック ゲーエムベーハー|Stabilized protein composition based on semifluorinated alkanes|
    CA2883002C|2012-09-12|2019-05-21|Novaliq Gmbh|Compositions comprising mixtures of semifluorinated alkanes|
    KR102115111B1|2012-09-12|2020-05-26|노바리크 게엠베하|Semifluorinated alkane compositions|
    GB2511028A|2012-12-18|2014-08-27|Univ Manchester Metropolitan|Nano emulsions, methods of forming the same and uses thereof|
    EP2783703A1|2013-03-25|2014-10-01|B. Braun Melsungen AG|Semifluorocarbon compound containing contrast agent|
    CN114028560A|2013-07-23|2022-02-11|诺瓦利克有限责任公司|Stabilized antibody compositions|
    CN112641720A|2014-03-03|2021-04-13|诺华股份有限公司|Lipoic acid choline ester compositions and methods of use|
    MX2018003781A|2015-09-30|2018-09-12|Novaliq Gmbh|Semifluorinated compounds for ophthalmic administration.|
    US20170087100A1|2015-09-30|2017-03-30|Novaliq Gmbh|Semifluorinated compounds and their compositions|
    CA3027767A1|2016-06-23|2017-12-28|Novaliq Gmbh|Topical administration method|
    AU2017329983A1|2016-09-23|2019-04-04|Novaliq Gmbh|Ophthalmic compositions comprising ciclosporin|
    US10717691B2|2017-05-05|2020-07-21|Novaliq Gmbh|Process for the production of semifluorinated alkanes|
    EP3912621A4|2020-05-19|2021-11-24|Tesa Labtec Gmbh|Propofol for diagnosis of primary headache|
    FR3112475A1|2020-07-20|2022-01-21|Naos Institute Of Life Science|ecobiological formulation, compatible with cellular life, usable in the cosmetic, dermopharmaceutical or veterinary fields|
    法律状态:
    2018-01-16| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|
    2018-04-03| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|
    2018-07-31| B07E| Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|
    2019-01-22| B06T| Formal requirements before examination [chapter 6.20 patent gazette]|
    2021-06-01| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|
    2021-06-08| B350| Update of information on the portal [chapter 15.35 patent gazette]|
    2021-08-03| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/01/2012, OBSERVADAS AS CONDICOES LEGAIS. |
    优先权:
    申请号 | 申请日 | 专利标题
    EP11150064|2011-01-04|
    EP11150064.1|2011-01-04|
    PCT/EP2012/050043|WO2012093113A1|2011-01-04|2012-01-03|O/w-emulsions comprising semifluorinated alkanes|
    [返回顶部]